Pieris Pharmaceuticals, Inc.
PIRS
Price:
$16.7747
Market Cap:
$22.15M
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; ...[Read more]
Industry
Biotechnology
IPO Date
2015-01-02
Stock Exchange
NASDAQ
Ticker
PIRS
PE Ratio
[-1.39]
ROE
[-76.24%]
Current Ratio
[4.82]
Dividend Yield
[0%]
Enterprise Value
[2.78M]
Dividend History
The ROE as of November 2024 (TTM) for Pieris Pharmaceuticals, Inc. (PIRS) is -76.24%
According to Pieris Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -76.24%. This represents a change of 299.48% compared to the average of -19.09% of the last 4 quarters.
Pieris Pharmaceuticals, Inc. (PIRS) Historical ROE (quarterly & annually)
How has PIRS ROE performed in the past?
The mean historical ROE of Pieris Pharmaceuticals, Inc. over the last ten years is -86.57%. The current -76.24% ROE has changed -11.93% with respect to the historical average. Over the past ten years (40 quarters), PIRS's ROE was at its highest in in the December 2017 quarter at 65.01%. The ROE was at its lowest in in the September 2017 quarter at -154.86%.
Average
-86.57%
Median
-87.91%
Minimum
-153.16%
Maximum
-45.16%
Pieris Pharmaceuticals, Inc. (PIRS) ROE by Quarter and Year
Discovering the peaks and valleys of Pieris Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 159.39%
Maximum Annual ROE = -45.16%
Minimum Annual Increase = -583.43%
Minimum Annual ROE = -153.16%
| Year | ROE | Change |
|---|---|---|
| 2023 | -91.72% | -18.03% |
| 2022 | -111.90% | 30.97% |
| 2021 | -85.44% | -28.79% |
| 2020 | -119.99% | 159.39% |
| 2019 | -46.26% | -30.95% |
| 2018 | -66.99% | -56.26% |
| 2017 | -153.16% | 69.47% |
| 2016 | -90.38% | 100.11% |
| 2015 | -45.16% | -17.44% |
| 2014 | -54.70% | -583.43% |
Pieris Pharmaceuticals, Inc. (PIRS) Average ROE
How has PIRS ROE performed in the past?
The current ROE of Pieris Pharmaceuticals, Inc. (PIRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-96.36%
5-year avg
-91.06%
10-year avg
-86.57%
Pieris Pharmaceuticals, Inc. (PIRS) ROE vs. Peers
How is PIRS’s ROE compared to its peers?
Pieris Pharmaceuticals, Inc.’s ROE is greater than Adaptimmune Therapeutics plc (-74.84%), greater than Mereo BioPharma Group plc (-69.11%), greater than PDS Biotechnology Corporation (-139.57%), greater than Leap Therapeutics, Inc. (-116.24%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Corvus Pharmaceuticals, Inc. (-167.55%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than TCR2 Therapeutics Inc. (-71.90%), greater than Affimed N.V. (-193.85%), less than ADC Therapeutics SA (131.30%), less than Agenus Inc. (131.89%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Achilles Therapeutics plc (-54.57%), less than Checkpoint Therapeutics, Inc. (359.97%), greater than Cue Biopharma, Inc. (-156.38%), greater than Medicenna Therapeutics Corp. (-26.16%),
| Company | ROE | Market cap |
|---|---|---|
| -74.84% | $176.64M | |
| -69.11% | $575.61M | |
| -139.57% | $78.19M | |
| -116.24% | $97.71M | |
| -32.51% | $57.64M | |
| -167.55% | $575.10M | |
| -32.76% | $491.80M | |
| -71.90% | $58.11M | |
| -193.85% | $39.90M | |
| 131.30% | $192.41M | |
| 131.89% | $78.35M | |
| -88.42% | $180.51M | |
| -54.57% | $43.57M | |
| 359.97% | $180.50M | |
| -156.38% | $64.62M | |
| -26.16% | $0 |
Build a custom stock screener for Pieris Pharmaceuticals, Inc. (PIRS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pieris Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Pieris Pharmaceuticals, Inc. (PIRS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Pieris Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Pieris Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the highest ROE for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the 3-year average ROE for Pieris Pharmaceuticals, Inc. (PIRS)?
What is the 5-year average ROE for Pieris Pharmaceuticals, Inc. (PIRS)?
How does the current ROE for Pieris Pharmaceuticals, Inc. (PIRS) compare to its historical average?